News

May 1, 2020

Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19

Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19 Implementation has enabled Obsidian to remain on track to meet development targets, while […]
March 3, 2020

Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors

Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors March 3, 2020, 07:00 AM Eastern Standard Time CAMBRIDGE, Mass., March 3, 2020 – Obsidian Therapeutics, a biotechnology […]
February 5, 2020

Obsidian Therapeutics Announces Formation of Scientific Advisory Board

Obsidian Therapeutics Announces Formation of Scientific Advisory Board Members will help to guide the development strategy of existing pipeline as well as identify innovative applications for […]
November 12, 2019

Obsidian Therapeutics Announces Expansion of Leadership Team

Obsidian Therapeutics Announces Expansion of Leadership Team Additions support Obsidian’s active program development, operational build-out and ongoing regulatory discussions Nov. 12, 2019, 08:00 AM Eastern Standard […]
September 24, 2019

Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources

Obsidian Therapeutics Appoints Erin Boyer as Vice President, Human Resources Sept. 24, 2019 07:30 AM Eastern Daylight Time CAMBRIDGE, Mass., Sept. 24, 2019 – Obsidian Therapeutics, a […]
July 25, 2019

Obsidian Therapeutics Announces Strengthening of Executive Leadership Team

Obsidian Therapeutics Announces Strengthening of Executive Leadership Team Expanded Leadership Supports Company Evolution into Development-Stage Biotechnology Company using cytoDRiVE™ Technology to Regulate Cell and Gene Therapies […]
April 18, 2019

Obsidian Therapeutics Announces Leadership Transition

Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer Experienced CEO brings expertise in product development, cell and gene therapies, […]
January 18, 2019

Obsidian Therapeutics Announces Strategic Collaboration with Celgene

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New […]
December 6, 2017

Obsidian Therapeutics Announces $49.5 Million Series A Financing

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products Financing led by GV to focus on lead programs for […]